【實用醫療app】AF Global Calculator (EUROPE)|最夯免費app-綠色工廠好玩App

This application is proposed as a simple but effective aid to the indication for antithrombotic therapy in non-valvular atrial fibrillation, based on ESC guidelines.

In just ONE SCREEN, essential parameters are entered and displayed the results: the scores of thromboembolic risk (CHADSVASC), haemorrhagic risk (HASBLED) and glomerular filtration rate (Cockcroft-Gault formula). Finally, always in the same screen, are shown the resulting antithrombotic therapies, in adherence to the ESC guidelines.

At the bottom of the screen data are entered:

- gendre

- age, weight (kg) and serum creatinine (mg/dL) , with keys (+) and (-) sensible to short or long click, for a quick and easy insertion of the values

- check-list of 12 clinical-anamnestic items.

Based on the data entered, the calculated results are automatically displayed in the upper section of the screen:

At the top right are shown the scores CHADSVASC, HASBLED and creatinine clearance calculated by the Cockcroft-Gault formula.

In the upper left shows the resulting therapeutic indications based on ESC guidelines 2012: three "traffic lights" appearing green or red for the three treatment options:

1) no antithrombotic therapy (NONE)

2) vitamin K antagonists (VKA)

3) New Oral Anticoagulants (NOAC).

For Italy we suggest our specific application, "AF Global Calculator (ItalY), based also on AIFA (Agenzia Italiana del Farmaco) restriction for Dabigatran's prescription.

DISCLAIMER : The author assumes no responsibility for use of this application and invites who use it to verify the results provided and adapt them to the clinical context.

The "AF Global Calculator (Europe)", on the Android platform, was developed entirely (drafting of the algorithm, technical development, graphics solutions) by Dr. Francesco Gemelli, Cardiologist in Rome.

We welcome any comments or suggestions that can be sent to the following address: franc.gemelli@gmail.com

KEY-WORDS: Medical Calculator, Cardiology, ESC, guidelines European Society of Cardiology, Atrial Fibrillation, anticoagulant, antithrombotic, embolic risk, stroke risk, HASBLED, CHADSVASC, CHA2DS2-VASC, Dabigatran, Rvaroxaban, Epixaban